| Name | Title | Contact Details |
|---|
Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.
Impel NeuroPharma is a Seattle-based company developing intranasal drug treatments for central nervous system (CNS) disorders. Impel has developed a novel drug delivery platform, the POD technology, that administers drug to the deep nasal cavity to improve the brain distribution of many drugs. Impel`s proprietary (POD) device technology enables entirely new categories of drugs, including biologics, to be delivered to the central nervous system using a cost-effective, disposable, non-invasive intranasal drug delivery device.
Glaukos Corporation is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world`s leading causes of blindness. Glaukos has pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. The company launched the iStent Trabecular Micro-Bypass Stent, its first MIGS device, in the United States in 2012. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of injectable micro-scale therapies designed to address the complete range of glaucoma disease states and progression. Glaukos believes the iStent is the smallest medical device ever approved by the Food and Drug Administration, or FDA, measuring 1.0 mm long and 0.33 mm wide. In June 2015, the company completed an initial public offering and its shares are now traded on the New York Stock Exchange under the ticker symbol "GKOS". Founded in 1998, Glaukos is based in San Clemente, California.
Leis Medical is a Vandalia, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company`s CorPath® System is the first FDA-cleared medical device to bring robotic-assisted precision to radial, coronary and peripheral procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance stents and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. With the CorPath System, Corindus Vascular Robotics brings robotic precision to radial and complex interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement with manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program."